Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

84.50CHF
16 Oct 2017
Change (% chg)

CHF0.60 (+0.72%)
Prev Close
CHF83.90
Open
CHF84.05
Day's High
CHF84.65
Day's Low
CHF83.95
Volume
3,106,177
Avg. Vol
4,388,352
52-wk High
CHF84.65
52-wk Low
CHF67.40

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.05
Market Cap(Mil.): CHF219,373.20
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.75
Yield (%): 3.28

Financials

  Industry Sector
P/E (TTM): -- 31.52 16.83
EPS (TTM): -- -- --
ROI: -- 14.97 10.92
ROE: -- 16.23 14.52

Deals of the day-Mergers and acquisitions

Oct 11 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:

Oct 11 2017

Novartis decides not to sell Roche stake chairman tells newspaper

ZURICH Novartis has decided not to sell its roughly $14 billion (10.61 billion pounds), 33 percent voting stake in Roche following a review, Chairman Joerg Reinhardt said in an interview published on Wednesday in Swiss newspaper HandelsZeitung.

Oct 11 2017

Novartis decides not to sell Roche stake chairman tells newspaper

ZURICH, Oct 11 Novartis has decided not to sell its roughly $14 billion, 33 percent voting stake in Roche following a review, Chairman Joerg Reinhardt said in an interview published on Wednesday in Swiss newspaper HandelsZeitung.

Oct 11 2017

BRIEF-Argentum Pharmaceuticals succeeds in starting patent cancellation trial against Novartis' AFINITOR

* Argentum Pharmaceuticals says succeeds in starting patent cancellation trial against Novartis' AFINITOR

Sep 29 2017

UPDATE 1-Novartis forges UC Berkeley pact, sees drug hopefuls in 3 years

ZURICH, Sept 28 Novartis's research head expects an alliance with a University of California chemistry lab to produce drug candidates within three years as the Swiss company accelerates its hunt for new medicines.

Sep 28 2017

Three tips for smart dividend ETF plays

NEW YORKPop quiz: What percentage of long-term stock market returns are thanks to the humble dividend? Five? 10? 20?

Sep 21 2017

RPT-YOUR MONEY-Three tips for smart dividend ETF plays

NEW YORK, Sept 21Pop quiz: What percentage of long-term stock market returns are thanks to the humble dividend? Five? 10? 20?

Sep 21 2017

YOUR MONEY-Three tips for smart dividend ETF plays

NEW YORK, Sept 21Pop quiz: What percentage of long-term stock market returns are thanks to the humble dividend? Five? 10? 20?

Sep 21 2017

Novartis's Rydapt wins EU approval for AML, other diseases

ZURICH Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals the medicine secured in April.

Sep 20 2017

Novartis's Rydapt wins EU approval for AML, other diseases

ZURICH Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals the medicine secured in April.

Sep 20 2017

Earnings vs. Estimates